Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy

Adv Drug Deliv Rev. 2022 Jul:186:114321. doi: 10.1016/j.addr.2022.114321. Epub 2022 May 6.

Abstract

Bacterial membrane vesicles (BMVs) have emerged as novel and promising platforms for the development of vaccines and immunotherapeutic strategies against infectious and noninfectious diseases. The rich microbe-associated molecular patterns (MAMPs) and nanoscale membrane vesicle structure of BMVs make them highly immunogenic. In addition, BMVs can be endowed with more functions via genetic and chemical modifications. This article reviews the immunological characteristics and effects of BMVs, techniques for BMV production and modification, and the applications of BMVs as vaccines or vaccine carriers. In summary, given their versatile characteristics and immunomodulatory properties, BMVs can be used for clinical vaccine or immunotherapy applications.

Keywords: Genetic engineering; Tumor immunotherapy; Vaccine; bacterial membrane vesicle (BMV); outer membrane vesicle (OMV).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacteria
  • Humans
  • Immunity
  • Immunotherapy
  • Neoplasms* / therapy
  • Vaccines*

Substances

  • Vaccines